Baratte, B. | IICIMED

Baratte, B.

Publications

P300

RSC Med. Chem. 2025, 16, 3746–3763. 

 Pharmacophore-guided optimization of the hit compound CTN1122 in the design of promising imidazo[1,2-a]pyrazine derivatives targeting the casein kinase 1 for antileishmanial therapy


https://doi.org/10.1039/D5MD00257E

P290

ChemMedChem. 2025, 20, e202400862.

Investigating the C2 modulation of the imidazo[1,2-a]pyrazine-based hit compound CTN1122: synthesis, in vitro antileishmanial activity, cytotoxicity and casein kinase 1 inhibition.


https://doi.org/10.1002/cmdc.202400862

P285

Int. J. Pharm. Res. Al. Sci. 2024, 13, 1-11.

Design and synthesis of functionalized 2,4-diamino-1,3,5-triazines, potential inhibitors involved in immune and inflammatory response.


https://doi.org/10.51847/hsT2C61XWx

P240

Molecules 2021, 26, 6572.

Dibenzofuran derivatives inspired from cercosporamide as dual inhibitors of Pim and CLK1 kinases.


doi: 10.3390/molecules26216572

P231

Eur. J. Med. Chem. 2021, 210, 112956.

In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition.


doi: 10.1016/j.ejmech.2020.112956

P173

Bioorg. Med. Chem. Lett. 2018, 28, 2250-2255.

Benzofuro[3,2-d]pyrimidines inspired from cercosporamide CaPkc1 inhibitor: synthesis and evaluation of fluconazole susceptibility restoration.


doi: 10.1016/j.bmcl.2018.05.044

P136

Eur. J. Med. Chem. 2015, 103, 381-395.

Synthesis, antileishmanial activity and cytotoxicity of 2,3-diaryl- and 2,3,8-trisubstituted imidazo[1,2-a]pyrazines.


doi: 10.1016/j.ejmech.2015.09.002

Autres publications scientifiques

PS36

Pharmaceuticals 2025, 18, 837.

New insights into the anticancer effects and toxicogenomic safety of two β-Lapachone derivatives.


https://doi.org/10.3390/ph18060837

Brevets

Thèse